web analytics

Blue California completes groundbreaking human clinical trial on ErgoActive®

Blue California, a pioneer in science-driven ingredient development, has achieved a significant breakthrough with the successful completion of a groundbreaking human clinical trial on ErgoActive® ergothioneine.

The double-blinded placebo-controlled trial, sponsored by Blue California, demonstrated the positive impact of ErgoActive® on cognitive function, memory, and sleep in healthy elderly subjects with subjective memory complaints.

Linda May-Zhang, Ph.D., VP of Science and Innovation at Blue California, expressed pride in sponsoring such a pivotal study, stating,

« We are pleased by the results showing improvements of cognitive function and ability to get to sleep in subjects consuming ErgoActive for four months. »

Research has long indicated that insufficient levels of ergothioneine are linked to various health issues, including cardiovascular disease, age-related cognitive decline, and neurodegenerative diseases like Parkinson’s and Alzheimer’s. Mushroom consumption, previously associated with cognitive benefits, laid the groundwork for this clinical trial.

Dr. Robert B. Beelman, Professor Emeritus of Food Science at Pennsylvania State University, emphasized the study’s significance, calling ergothioneine a ‘longevity vitamin’ that can help mitigate cognitive decline and sleep issues associated with aging.

Blue California, a gold sponsor for the National University of Singapore’s Center of Healthy Longevity global conference, highlighted the success of ErgoActive® ergothioneine.

The ingredient, produced by precision fermentation with FDA-reviewed safety of GRAS, offers versatility for formulation in dietary supplements, functional foods, beverages, pet supplements, and cosmetics.

Verified by MonsterInsights